mild-persistent asthma
Jump to navigation
Jump to search
Clinical manifestations
- beta-gonist use > 2 days/week, but < daily
- asthma-related night-time wakenings > 2 nights/month, but < 1 night/week
Diagnostic procedures
Management
- inhaled glucocorticoid
- budesonide MDI BID or equivalent
- more symptom-free days
- low-dose budesonide-formoterol preferred maintenace & rescue therapy if use of albuterol inhaler several times per week[2][3]
- oral leukotriene receptor antagonist
- zafirlukast
- may be of little value
- inhaled beta-adrenergic agonist PRN
- albuterol MDI (low-dose budesonide-formoterol preferred)
More general terms
References
- ↑ Journal Watch 25(10):84, 2005 Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, Chinchilli VM, Craig TJ, Dimango EA, Deykin A, Fagan JK, Fish JE, Ford JG, Kraft M, Lemanske RF Jr, Leone FT, Martin RJ, Mauger EA, Pesola GR, Peters SP, Rollings NJ, Szefler SJ, Wechsler ME, Israel E; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med. 2005 Apr 14;352(15):1519-28. PMID: https://pubmed.ncbi.nlm.nih.gov/15829533
- ↑ 2.0 2.1 Medical Knowledge Self Assessment Program (MKSAP) 20 American College of Physicians, Philadelphia 2025
- ↑ 3.0 3.1 Beasley R, Harrison T, Peterson S, et al. Evaluation of budesonide-formoterol for maintenance and reliever therapy among patients with poorly controlled asthma: a systematic review and meta-analysis. JAMA Netw Open. 2022;5:e220615. PMID: https://pubmed.ncbi.nlm.nih.gov/35230437 PMCID: PMC8889464 https://pmc.ncbi.nlm.nih.gov/articles/PMC8889464/
- ↑ http://www.nhlbi.nih.gov/health/prof/lung/asthma/practgde/practgde.pdf